Interestingly, chidamide, which targets HDAC1, 2, 3, and 10, also belongs to the benzamide class but exerts obvious anti-tumor immunity effect in relapsed and refractory peripheral T cell lymphoma and acute myeloid leukemia (Li et al., 2015; Chan et al., 2017). This evidence concerns the gene HDAC1 and neoplasm.